Livzon drug hits primary endpoint in psoriasis trial
Livzon Pharmaceutical Group announced its experimental drug LZM012 achieved the primary endpoint in a Phase III trial for moderate-to-severe plaque psoriasis.
The trial showed a PASI 100 response rate of 49.5% for LZM012 at week 12, surpassing the secukinumab control group's 40.2%. LZM012 also demonstrated faster onset with a 65.7% PASI 75 response rate at week 4, compared to 50.3% for the control group.
Long-term efficacy at week 52 showed PASI 100 rates of 75.9% and 62.6% for different dosing regimens. The drug's safety profile was comparable to the control group.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Livzon Pharmaceutical Group Inc publishes news
Free account required • Unsubscribe anytime